The risk of cardiac events and genotype-based management of LQTS patients

Annals of Noninvasive Electrocardiology

Volumn 14, Issue 1, 2009, Pages 86-92

  Markiewicz ŁOskot, Grazyna ^a   Moric Janiszewska, Ewa ^a,b   Mazurek, Urszula ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Department of Biochemistry ^*  (Poland)

Author keywords

Arrhythmias; Beta blocker therapy; Congenital long QT syndrome; Genotype phenotype correlation; Ion channel

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; FLECAINIDE; ION CHANNEL; LIDOCAINE; MAGNESIUM SULFATE; MEMBRANE PROTEIN; MEXILETINE; NICORANDIL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHLORIDE; SCAFFOLD PROTEIN; SODIUM CHANNEL BLOCKING AGENT; SPIRONOLACTONE; STRUCTURAL ANCHORING PROTEIN; STRUCTURAL PROTEIN; TOCAINIDE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ARTIFICIAL HEART PACEMAKER; CARDIOVASCULAR RISK; CERVICOTHORACIC GANGLIONECTOMY; DEFIBRILLATOR; DISEASE ASSOCIATION; DRUG EFFICACY; ELECTIVE SURGERY; GANGLIONECTOMY; GENE IDENTIFICATION; GENE MUTATION; GENE THERAPY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC DISORDER; GENOTYPE; HEART ARRHYTHMIA; HEART DISEASE; HEART PACING; HEREDITY; HUMAN; LIFESTYLE MODIFICATION; LONG QT SYNDROME; LOW DRUG DOSE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SUDDEN DEATH; TACHYCARDIA; TORSADE DES POINTES;

ADRENERGIC BETA-ANTAGONISTS; CARDIAC PACING, ARTIFICIAL; COMBINED MODALITY THERAPY; DEFIBRILLATORS, IMPLANTABLE; FEMALE; GANGLIONECTOMY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LONG QT SYNDROME; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 58649106215     PISSN: 1082720X     EISSN: 1542474X     Source Type: Journal    
DOI: 10.1111/j.1542-474X.2008.00278.x     Document Type: Review

References (84)

1. Schwartz PJ, Moss AJ, Vincent GM, et al. Diagnostic criteria for the long QT syndrome. An update. Circulation 1993 88 : 782 784.
2. Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation 1991 84 : 1136 1144.
3. Splawski I, Shen J, Timothy KW, et al. Genomic structure of three long QT syndrome genes: KVLQT1, HERG, and KCNE1. Genomics 1998 51 : 86 97.
4. Splawski I, Shen J, Timothy KW, et al. Spectrum of mutations in long-QT syndrome genes KVLQT1, HERG, SCN5A, KCNE1 and KCNE2. Circulation 2000 102 : 1178 1185.
5. Mohler PJ, Schott JJ, Gramolini AO, et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 2003 421 : 634 639.
6. Plaster MN, Tawil R, Tristani-Firouzi M, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 2001 105 : 511 519.
7. Splawski I, Timothy KW, Sharpe IM, et al. Ca(V) 1,2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004 119 : 19 31.
8. Barrett CF, Tsien RW. The Timothy syndrome mutation differentially affects voltage- and calcium-dependent inactivation of Cav1.2 L-type calcium channels. PNAS 2008 6 : 2157 2162.
9. Erxleben CH, Liao Y, Gentile S, et al. Cyclosporin and Timothy syndrome increase mode 2 gating of CaV1,2 calcium channels through aberrant phosphorylation of S6 helices. PNAS 2006 103 : 3932 3937.
10. Vatta M, Ackerman MJ, Ye B, et al. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation 2006 114 : 2104 2112.
11. Chen L, Marquardt ML, Tester DJ, et al. Mutation of an A-kinase-anchoring protein causes long QT syndrome. PNAS 2007 52 : 20990 20995.
12. Medeiros-Domingo A, Kaku T, Tester DJ, et al. SCN4B encoded sodium channel 4 subunit in congenital long QT syndrome. Circulation 2007 116 : 134 142.
13. Moss AJ. T-Wave patterns associated with the hereditary long QT syndrome. CEPR 2002 6 : 311 315.
14. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome gene-specific triggers for life-threatening arrhythmias. Circulation 2001 103 : 89 95.
15. Moss AJ, Robinson JL, Gessman L, et al. Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. Am J Cardiol 1999 84 : 876 879.
16. Ackerman MJ, Tester DJ, Porter CJ. Swimming, a gene-specific arrhythmogenic trigger for inherited long QT syndrome. Mayo Clin Proc 1999 74 : 1088 1094.
17. Wilde AAM, Jongbloed RJE, Doevendans PA, et al. Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1). J Am Coll Cardiol 1999 33 : 327 332.
18. Antzelevitch C, Oliva A. Amplification of spatial dispersion of repolarization underlies sudden cardiac death associated with catecholaminergic polymorphic VT, long QT and Brugada syndromes. J Intern Med 2006 259 : 48 58.
19. Roden DM, Spooner PM, et al. Inherited long QT syndromes: A paradigm for understanding arrhythmo-genesis. J Cardiovasc Electrophysiol 2000 10 : 1664 1683.
20. Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome: A prospective international study. Circulation 1985 71 : 17 21.
21. Moss AJ. Prolonged QT syndrome. JAMA 1986 256 : 2985 2987.
22. Goldenberg I, Moss AJ, Peterson DR, et al. Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation 2008 117 : 2184 2191.
23. Hobbs JB, Peterson DR, Moss AJ, et al. Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA 2006 296 : 1249 1254.
24. Sauer AJ, Moss AJ, McNitt S, et al. Long QT syndrome in adults. J Am Coll Cardiol 2007 49 : 329 337.
25. Goldenberg I, Moss AJ, Bradley J, et al. Long-QT syndrome after age 40. Circulation 2008 117 : 2192 2201.
26. Shimizu W, Antzelevitch C. Cellular basis for the electrocardiographic features of the LQTS1 form of the long QT syndrome: Effects of beta-adrenergic agonists, antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation 1998 98 : 2314 2322.
27. Shimizu W, Antzelevitch C. Differential effects of beta-adrenergic agonists and antagonists in LQTS1, LQTS2, and LQTS3 models of the long QT syndrome. J Am Coll Cardiol 2000 35 : 778 786.
28. Shimizu W, Antzelevitch C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 and LQT3 models of the long QT syndrome. Circulation 1997 96 : 2038 2047.
29. Shimizu W, Tanabe Y, Aiba T, et al. Differential effects of beta-blockade on dispersion of repolarization in the absence and presence of sympathetic stimulation between the LQT1 and LQT2 forms of congenital long QT syndrome. J Am Coll Cardiol 2002 39 : 1894 1896.
30. Tanabe Y, Inagaki M, Kurita T, et al. Sympathetic stymulation produces a greater increase in both transmural and special dispersion of repolarization in LQT1 than LQT2 forms of congenital long QT syndrome. J Am Coll Cardiol 2001 37 : 911 919.
31. Khositseth A, Nemec J, Hejlik J, et al. Effect of phenylephrine provocation on dispersion of repolarization in congenital long QT syndrome. ANE 2003 8 : 208 214.
32. Conrath CE, Wilde AAM, Jongbloed RJE, et al. Gender differences in the long QT syndrome: Effects of B-adrenoceptor blockade. Cardiovasc Res 2002 53 : 770 776.
33. Batra AS, Silka MJ. Mechanism of sudden cardiac arrest while swimming in a child with the prolonged QT syndrome. J Pediatr 2002 141 : 283 284.
34. Zareba W, Moss AJ, Schwarzt PJ, et al. Influence of the genotype on the clinical course of the long-QT syndrome. N Engl J Med 1998 339 : 960 965.
35. Van Langen IM, Birnie E, Alders M, et al. The use of genotype-phenotype correlations in mutations analysis for the long QT syndrome. J Med Genet 2003 40 : 141 145.
36. Zareba W, Moss AJ. Long QT syndrome in children. J Electrocardiol 2001 34 (Suppl. 167 171.
37. Zareba W, Moss AJ, Locati EH, et al. Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. J Am Coll Cardiol 2003 42 : 103 109.
38. Goldenberg I, Mathew J, Moss AJ, et al. Corrected QT variability in serial electrocardiograms in long QT. J Am Coll Cardiol 2006 48 : 1047 1052.
39. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003 348 : 1866 1874.
40. Hofman N, Wilde AA, Kaab S, et al. Diagnostic criteria for congenital long QT syndrome in the era of molecular genetics: Do we need a scoring system? Eur Heart J 2007 28 : 575 580.
41. Kimbrough J, Moss AJ, Zareba W, et al. Clinical implications for affected parents and siblings of probants with the long-QT syndrome. Circulation 2001 104 : 557 562.
42. Goldenberg I, Moss AJ, Zareba W, et al. Clinical course and risk stratification of patients affected with the Jervell and Lange-Nielsen syndrome. J Cardiovasc Electrophysiol 2006 17 : 1161 1168.
43. Moss AJ, Zareba W, Kaufman ES, et al. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation 2002 105 : 794 799.
44. Moss AJ, Shimizu W, Wilde AA, et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation 2007 115 : 2481 2489.
45. Schwartz PJ, Locati E. Idiopathic long QT syndrome: Pathogenic mechanism and therapy. Eur Heart J 1985 6 : 103 114.
46. Moss AJ. Management of patients with the hereditary long QT syndrome. J Cardiovasc Electrophysiol 1998 9 : 668 674.
47. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 2000 101 : 616 623.
48. Viskin S, Fish R. Prevention of ventricular arrhythmias in the congenital long QT syndrome. Curr Cardiol Rep 2000 2 : 492 497.
49. Eldar M, Griffin JC, Van Hare GF, et al. Combined use of beta-adrenergic blocking agents and long-term cardiac pacing for patients with the long QT syndrome. J Am Coll Cardiol 1992 3 : 830 837.
50. Dorostkar PC, Eldar M, Belhassen B, et al. Long-term follow-up of patients with long QT syndrome treated with beta-blockers and continuous pacing. Circulation 1999 100 : 2431 2436.
51. Moss AJ, Liu JE, Gottlieb S, et al. Efficacy of permanent pacing in the management of high-risk patients with long-QT syndrome. Circulation 1991 84 : 1524 1529.
52. Viskin S. Cardiac pacing in the long QT syndrome: Review of available data and practical recommendations. J Cardiovasc Electrophysiol 2000 11 : 593 600.
53. Moss AJ, McDonald J. Unilateral cervicothoracic sympathetic ganglionectomy for the treatment of long QT interval syndrome. N Engl J Med 1970 285 : 903 904.
54. Schwartz PJ, Locati E, Moss AJ, et al. Left cardiac sympathetic denervation in the therapy of the congenital long QT syndrome: A worldwide report. Circulation 1991 84 : 503 511.
55. Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long QT syndrome. Circulation 2004 109 : 1826 1833.
56. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death-executive summary. A report if the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines. Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J 2006 27 : 2009 2140.
57. Zareba W, Moss AJ, Daubert JP, et al. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol 2003 14 : 337 341.
58. Etheridge SP, Sanatani S, Cohen MI, et al. Long QT syndrome in children in the era of implantable defibrillators. J Am Coll Cardiol 2007 50 : 1335 1340.
59. Moric-Janiszewska E, Markiewicz-Łoskot G, Łoskot M, et al. Challenges of diagnosis of long QT syndrome in children. PACE 2007 30 : 1168 1170.
60. Carlsson L, Abrahamsson C, Drews L, et al. Antyarrhythmic effects of potassium channel openers in rhythm abnormalities related to delayed repolarization. Circulation 1992 85 : 1491 1500.
61. + channel opener in the LQT1 form of congenital long QT syndrome. Circulation 1998 97 : 1581 1588.
62. Aizawa Y, Uchiyama H, Yamamura M, et al. Effect of the ATP-sensitive K channel opener nicorandil on the QT interval and the effective refractory period in patients with congenital long QT syndrome. J Electrocardiol 1998 31 : 117 123.
63. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 2004 292 : 1341 1344.
64. Compton SJ, Lux RL, Ramsey MR, et al. Genetically defined therapy of inherited long OT-syndrome. Correction of abnormal repolarization by potassium. Circulation 1996 94 : 1018 1022.
65. Tan HL, Alings M, Van Olden RW, et al. Long-term (subacute) potassium treatment in congenital HERG-related long QT syndrome (LQTS2). Cardiovasc. Electrophysiol 1999 10 : 229 233.
66. Etheridge SP, Compton JS, Tristani-Firouzi M, et al. A new oral therapy for long QT syndrome. Long-term oral potassium improves repolarization in patients with HERG mutations. J Am Coll Cardiol 2003 42 : 1777 1782.
67. + channel blockade and to increases in heart rate: Implications for gene-specific therapy. Circulation 1995 92 : 3381 3386.
68. Rosero SZ, Zareba W, Robinson JL, et al. Gene specific therapy for long QT syndrome: QT shortening with lidocaine and tocainide in patients with mutation of the sodium channel gene. ANEC 1997 2 : 274 278.
69. Ruan Y, Liu N, Bloise R, et al. Gating properties of SCN5A mutations and the response to mexiletine in syndrome type 3 patients. Circulation 2007 116 : 1137 1144.
70. Benhorin J, Taub R, Goldmit M, et al. Effect of flecainide in patients with new SCN5A mutation: Mutation specific therapy for long QT syndrome? Circulation 2000 101 : 1698 1706.
71. Windle JR, Geletka RC, Moss AJ, et al. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5a: deltaKPQ mutation. Ann Noninvasive Electrocardiol 2001 6 : 153 158.
72. Nagatomo T, January CT, Makielski JC. Preferential block of late sodium current in the LQT3 deltaKPQ mutant by in the class I(C) antiarrhythmic flecainide. Mol Pharmacol 2005 57 : 101 107.
73. Moss AJ, Windle JR, Hall WJ, et al. Safety and efficacy of flecainide in subject with long QT-3 syndrome (delta KPQ mutation): A randomized, double-blind, placebo-controlled clinical trial. Ann Noninvasive Electrocardiol 2005 10 : 59 66.
74. Kannankeril PJ, Roden DM, Fish FA. Suppression of bidirectional ventricular tachycardia and unmasking of prolonged QT interval with verapamil in Andersen's syndrome. J Cardiovasc Electrophysiol 2004 15 : 119.
75. Bokenkamp R, Wilde AA, Schalij MJ, et al. Flecainide for recurrent malignant ventricular arrhythmias in two siblings with Andersen-Tawil syndrome. Heart Rhythm 2007 4 : 508 511.
76. Pellizzon OA, Kalaizich L, Ptacek LJ, et al. Flecainide suppresses bidirectional ventricular tachycardia and reverses tachycardia-induced cardiomyopathy in Andersen-Tawil syndrome. J Cardiovasc Electrophysiol 2008 19 : 95 97.
77. Pelliccia A, Fagard R, Bjornstad HH, et al. Recommendations for competitive sports participation in athletes with cardiovascular disease. A consensus document from the Study Group of Sports Cardiology of the Working Group Cardiac Rehabilitation and Exercise Psychology and the Working Group of Myocardial and Pericardial Disease of the European Society of Cardiology. Eur Heart J 2005 26 : 1422 1445.
78. Corrado D, Pelliccia A, Bjornstad HH, et al. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: Proposal for a common European protocol. Consensus Statement of the Study Group of Sports Cardiology of the Working Group Cardiac Rehabilitation and Exercise Psychology and the Working Group of Myocardial and Pericardial Disease of the European Society of Cardiology. Eur Heart J 2005 26 : 516 524.
79. Napolitano C, Priori SG, Schwartz PJ, et al. Genetic testing in the long QT syndrome: Development and validation of an efficient approach to genotyping in clinical practice. JAMA 2005 294 : 2975 2980.
80. Priori SG. Long QT syndrome: Entering the era of molecular diagnosis. Heart 1997 77 : 5 6.
81. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long QT syndrome. Clinical impact. Circulation 1999 99 : 529 533.
82. Weese-Mayer DE, Ackerman MJ, Marazita ML, et al. Sudden infant death syndrome: Review of implicated genetic factors. Am J Med Genet A 2007 143 : 771 788.
83. Arnestad M, Crotti L, Rognum TO, et al. Prevalence of long-QT syndrome gene variants in sudden infant death. Circulation 2007 115 : 361 367.
84. Wang DW, Desai RR, Crotti L, et al. Cardiac sodium channel dysfunction in sudden infant death syndrome. Circulation 2007 115 : 368 376.